CHELATION THERAPY

Millions of people around the world suffer from atherosclerosis (hardening & narrowing of the arteries), high blood pressure, diabetes and other chronic diseases. Standard treatment for these conditions is different type of medicines, coronary artery bypass surgery or angioplasty (stents). Many patients are not satisfied with their current treatment and seek alternate treatments. One such treatment is chelation therapy.

The word chelate is derived from the Greek word chele, which refers to the claw of a crab or lobster, implying the firm, pincer-like binding action. Chelation therapy is a treatment in which a variety of specific compounds are administered IV or orally so as to bind or chelate & safely remove unwanted substances.

Several chelating agents are available such as EDTA, DMPS, DMSA, Plaquex, sodium alginate, cilantro, chlorella, MSM, certain amino acids and high dose vitamin C.

It is believed that toxic metals such as arsenic, lead, mercury, and cadmium and possibly excess amounts of iron or calcium, can accumulate in the arteries and other tissues of the body. This accumulation can lead to free radical damage, micro-inflammation and increased vulnerability to infection of the blood vessels, which in turn, initiates the process of atherosclerosis. Since these abnormal metals cannot be excreted efficiently by normal detoxification functions, a chelating agent is used to bind & remove these metals.

The ultimate effect of chelation therapy is to restore the health of the arteries. This is not only obtained by the removal of the pathological heavy metals, but also by increased production of a naturally formed substance called nitric oxide.

Nitric oxide, also called endothelial-relaxing factor, relaxes the blood vessels, and improves the blood flow and delivery of oxygen to the tissues.

EDTA CHELATION

IV Sodium EDTA Chelation is the most common chelation therapy used, typically 1-2 times per week for a minimum of 20 to 30 treatments. Each treatment runs over ~ 3 hours. Some individuals may need more therapy for sustained clinical improvement. Calcium EDTA which is slightly less effective than Sodium EDTA can also be used and only takes 5-60 minutes to administer.

Potential chelation therapy candidates are screened for pre-existing conditions that may make them unsuitable for this therapy and are rigorously monitored throughout the treatment.

This therapy has existed since the 1940s, when it was first introduced specifically for the treatment of lead poisoning, and has been fraught with controversy ever since. Conventional doctors still do not believe that it is effective treatment for atherosclerosis.

Chelation therapy is not a panacea and in certain individuals drug therapy and surgery are a necessity and must be used with or without chelation therapy. However, studies and clinical experience have shown that a majority of patients that undergo chelation show a definite improvement in circulation and arterial pulses. Other benefits include a return of normal temperature to the feet, regaining of ability to walk long distances comfortably, a decrease or elimination of chest pain, lowered blood pressure, improvement in brain function and muscle coordination. Many have no longer required certain drugs or bypass surgery. Some patients report improvement in arthritis pain.

Training for chelation therapy is available and provided to doctors by several organizations in the U.S., specifically, the American College for the Advancement of Medicine (ACAM). These groups arrange regular courses, conferences, updates and certification examinations and have developed the standard, safe, chelation protocols. This treatment is considered investigational and not covered by any health insurance plans.

WHAT IS PLAQUEX?

AAWC now offer "Plaquex or Plaque-X " treatments, a natural phospholipid from soybeans given  specifically to release arteriosclerotic plaque from the arteries of the body.  Plaquex was developed over 50 years ago in Germany, and used extensively around the world IV. 

Note:  Plaquex is phosphatydalcholine, also known as Essential Phospholipid or EPL, essential phospholipid exchange, Lipostabil, lecithin, and more.

After a course of Plaquex, to the amazement of researchers during clinical studies... patients with severe angina and coronary artery blockage were completely asymptomatic, and no longer needed heart medications ... such as beta blockers, nitroglycerin and blood pressure medications.

There are no side effects with Plaquex treatments except for positive side effects such as improved circulation to the brain, legs, heart and other vital organs. Occasionally loose stools occur during treatment, but this is controlled by lowering the dose.  Irritation of veins at the infusion site has occurred and this is reduced by lowering the dose, or diluting the phospholipid in a greater amount of IV fluid, or switching to a "plastic" needle.

Male patients suffering from sexual impotency because of poor blood circulation have noted an improvement during the course of treatment. Because of the ability of phospholipid  to cleanse all of the arteries in the body, patients may notice a dramatic improvement in kidney and cerebral function, sexual potency, and improved circulation in extremities with reduction or disappearance of symptoms. Plaquex also lowers LPa, cholesterol, fat deposits in liver, and more.    

Plaquex cannot be mixed with other intravenous materials.  It is generally given 1-5 times per week, for a course of 20-40 treatments.

Plaquex does not cure atherosclerosis; it just backs the plaque out, improving circulation. After the initial course of treatments, maintenance treatments are essential -- about one per month if the problem is mild and 2 or more per month if the disease is severe.

ESSENTIAL PHOSPHOLIPID EXCHANGE

Another name for Plaquex treatment, when done for reversal of chronic illnesses, is “Essential Phospholipid Exchange”.  In this procedure, a sterile syringe containing 15-40cc of phosphatydalcholine is mixed with an equal portion of the patient’s blood and re-injected into the patient’s vein in about 10 minutes.  See Patricia Kane, PhD’s book The Detoxx Book for complete information.  

EDTA CHELATION PLUS PLAQUEX!

The combined effects of EDTA Chelation Therapy with its ability to remove heavy metals, thinning calcified plaque, and its anti-oxidative qualities, mixed with the vessel-cleansing, cholesterol lowering qualities of Plaquex... is  “the dynamic duo” of atherosclerosis.  Dr. Deol recommends alternating 1 Plaquex and 1 EDTA Chelation each week, or alternatively 2 Plaquex and 1 EDTA treatment per week.

Treatments continue until symptoms are gone, and number of treatments varies from patient to patient, but approximately 30 Plaquex and 15 chelation treatments are recommended to start with. 

THE HISTORY OF PLAQUEX

A few years ago physicians stumbled onto a substance isolated from soy beans (which had been tested clinically 20 years prior in patients with severe coronary artery disease.  20 patients suffering with intractable chest pain, sustained on beta blockers and nitroglycerin products were entered into a program which consisted of an infusion over a period of 50-60 minutes, 3-5 times per week for a total of 30 treatments. 19 patients became symptom free and got off all their medicines.  

Based on the above results, a medical research team at BAXAMED, in Switzerland, initiated their own clinical study on a small group of severely ill patients.  Two of these patients already had  2 bypass operations and had been sent home to die, one patient had 2 angioplasties and was still suffering from angina pectoris, and a fourth patient was documented, by a thallium stress test, to have blood perfusion problems of his heart. 

After Plaquex treatment, a stress test at the University Hospital in Basel, Switzerland showed almost normal perfusion of the heart in all patients.

BENEFITS OF PLAQUEX
Plaquex Therapy fights "aging".

Plaquex reverses age-related damage to the body. As we age, billions of our cells change, especially in the cell membrane.  Cell membranes are composed of a variety of fatty substances called lipids, which occur in specific ratios. With aging the membrane’s lipid ratios and structures change and degrade. Slowly the cell loses its youthful elasticity. The cell membrane no longer admits nourishment into the cell and it no longer allows waste to leave.  

The cells “sleep" as if dead. These are the cells of your heart, lungs, kidneys, eyes, skin, liver, and most other tissues and organs of your body.

Plaquex Therapy reverses "age" related changes in the lipid ratios of the membrane of ALL THE CELLS OF THE BODY.

It returns the lipid ratio of the cell membrane to a ratio nearer that enjoyed by the individual in younger days. Cell membrane permeability normalizes and enzyme functions resume.  The cell returns to an earlier shape and a more youthful function.  The cell becomes more “elastic” again; nourishment gains entry into the cell; waste is removed. The cell awakens from its “near death sleep.” 

Because it has effects in the cell membranes of all cells, Plaquex has wide range of uses.

WHAT IS PLAQUEX BEING USED FOR?

1)  Revert cell, tissue, organ, and bodily functions to a younger state.
2)  Reverse or prevent the risk of plaque production.
3)  Help enhance the capacity for heart-lung stress. 
4)  Help to restore immunocompetence. 
5)  Enhance sexual competence. 
6)  Retard progression of aging. 
7)  Improve impaired renal and liver function. 
8)  Reduce high blood pressure, systolic and diastolic 
9)  Reverse myocardial hypertrophy (enlarged heart.) 
10) Reduce cholesterol & clean all arteries of the body.

 

View Chelation Powerpoint

Comprehensive & worth reviewing.

Chelation

CLINICAL STUDIES ON PLAQUEX or EPL

Significant decreases in anginal attacks (chest pain stage III and IV), or  in some patients total elimination of anginal attacks, as well as increased exercise tolerance of as much as 900% are reported by the following authors:
Almazov, VA. et al. Lipostabil Symp. Moscow, Nov 1984 
Almazov, VA. et at. Kardiologyia 26 (1986) 39 - 42
Hevelke G. et at. Med. Welt 30 (1980) 593 - 602
ltkina, L.D. et at. Lipostabil Symp. Moscow, Nov 1984
Seki, H et al. Gendai lryo 6 (1974) 599 - 618
Spesivtseva, V G. et al. Lipostabil Symp. Moscow, Nov 1984

The relative absorption rates of radioactive phospholipids in man were higher than 90%. The authors were able to show that approx. 40% - 80% of EPL absorbed were incorporated into the vasoprotective HDL (so called "good cholesterol"). The authors further concluded that part of the EPL was absorbed un-metabolized. This explains the relative long lifetime (48 hours) of liposomes in the human system.
Zierenberg, 0., 8.M Grundy, J Lipid Research 23 (1982) 1136-1142

In a documentation of 15 clinical trials with a duration of EPL treatment ranging between 1 and 12 months, total serum cholesterol was lowered by 8.8 to 28.2 %.
Faso/i, A., Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs; G. Ricci et al. (Eds) Raven Press: New York 1982, 257-262

In a double blind trial by the authors using 1.8 g oral EPL per day led to mean reductions of total cholesterol by 12.7 % already within 14 days of treatment. After another 4 weeks reduction of initial values totaled 18.9 %. 
Horsch A.K et aI., VASA 15 (1986) 275 - 279

After oral EPL treatment up to 16 weeks, average rates of cholesterol reduction in these studies that were either controlled against diet, double blind, controlled against placebo or were open, ranged from 12 to 25 % as compared with initial values.
Casellas Bernat, G. et al., Clin. Med 15 (1975) 90 - 95
Skorepa, J et aI., Casopis Lekaru Cekych 113 (1974) 784 - 786
Yasugi, T, Jap. J New Rem. Clin 22 (1973) 691 - 693

While diet alone did not produce satisfactory reductions (in lipid levels) in most cases, it clearly enhanced the effect of diets on serum lipids when applied together with EPL.
Knuechel, F. Die Medizinische 36 (1959) 1652 -1653
Varkonyi, G. Zschr. Ges. Med Grenzgeb. 18 (1962) 830 - 835

The following authors give a wide range of reduction of triglycerides with values 25% being the most common. 
Dewailli, P. et aI., Med Welt 36 (1985) 367 - 369
Yasugi, T, Jap. J New Rem. Clin. (1973) 691 - 693
Yoritsune, M et al., Gendai no Shinryo 22 (1980) 836 - 842

The author conducted a controlled study (32 participants) and reported average elevation in HDL cholesterol (so called "good cholesterol?) of 25 %.
Maeda, A. et al. Gendai no Shinryo 22 (1980) 189 -192 and 1461 -1465

The following authors give a wide range of reduction of triglycerides with values 25% being the most common.
Dewailli, P. et aI., Med Welt 36 (1985) 367 - 369
Yasugi, T, Jap. J New Rem. Clin. (1973) 691 - 693
Yoritsune, M et al., Gendai no Shinryo 22 (1980) 836 – 842

This author describes a significant inhibition of platelet adhesion as well as inhibition of platelet aggregation in blood after administration of oral EPL.
Coccheri. S. et al.. Acta. Med Scan 190 Suppl. 525 (1971) 253-256   

This author confirmed an improved passage of red blood cells through micro filters due to increased fluidity of the blood after injecting EPL.
Blagosklonov, s.s. et al., Kardiologyia 26 (1986) 35 - 38

AMA JOURNAL REPORT ON IV PHOSPHOLIPIDS

NOTE: Phospholipids extracted from soybeans are a natural molecule and cannot be patented.  Without a patent to protect the dollar-earning potential of phospholipids, no one will spend the millions needed to bring it to the public.  But a company has found a way to make “synthetic” phospholipids  by a recombinant process, and the process is patentable. The phospholipid recombinantly made is called ApoA-1 Milano (similar to phosphatidylcholine, “Plaquex”).  The following is excerpted from JAMA, Nov. 5, 2003.

Effect of Recombinant ApoA-1 Milano on Coronary Atherosclerosis in Patients with Acute Coronary Syndromes—A Randomized Controlled Trial. 
Nissen, MD, Tsunoda, MD, Schoenhagen, MD, et. al.

“...Infusion of recombinant ApoA-1 Milano-phospholipid complexes produces rapid regression of atherosclerosis in animal models.”

 “The study was a double blind, randomized, placebo controlled multi-centered pilot trial…   on coronary atheroma (plaque) burden measured by intra-vascular ultrasound (IVUS).”

 “… 123 patients aged 38-82 years consented, 57 were randomly assigned, 47 completed the protocol.”

 “… The absolute reduction in atheroma volume in the combined treatment group was … a 4.2% decrease from baseline.”

“Conclusions:  A recombinant ApoA-1 Milano/phospholipid complex (ETC-216) administered intravenously for 5 doses at weekly intervals produced significant regression of coronary atherosclerosis as measured by IVUS...

Editorial commentary: This well documented study parallels the clinical observations of symptom improvement noted by Plaquex doctors around the globe.

Note:  For every 1% increase in the internal diameter of a pipe, there is approximately a  4.9% increase in flow through the pipe.  Similarly, a small reduction in plaque volume begets a considerably larger improvement in blood flow, and often a considerable reduction in symptoms.
 

  There has been visits to this site.